Teva Slides 7% as R&D Chief Eric Hughes Exits Mid-Pivot
TEVA sits 63% above its 52-week low of $24.01.
Summary
Teva's EVP of Global R&D and Chief Medical Officer Eric Hughes resigned effective immediately after accepting an outside offer, and the stock fell nearly 7% Thursday. David Gardiner, currently head of Innovative Medicines & Clinical Development, takes over on an interim basis and reports directly to CEO Richard Francis while Teva launches an external search. The timing is awkward: Hughes' exit lands a week after Teva's first R&D Day, where it laid out $6-7B in innovative medicine revenue by 2030. Management says the R&D strategy and that 2030 target are unchanged, but losing the person who owned the pipeline is a real credibility test for the Pivot to Growth story. The move comes after a Q3 beat and raised guidance on November 3 and an at-home Igalmi label expansion on November 16, so this is the first negative headline in an otherwise strong run.
At the time of this announcement, TEVA was trading at $39.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $45.7B. The 52-week trading range was $24.01 to $44.57. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.